tiprankstipranks
Trending News
More News >

Taysha Gene Therapies price target raised to $6 from $5 at Citizens JMP

Citizens JMP raised the firm’s price target on Taysha Gene Therapies (TSHA) to $6 from $5 and keeps an Outperform rating on the shares. Taysha Gene Therapies reported positive clinical data from Part A of the REVEAL adult/ adolescent and pediatric cohorts evaluating TSHA-102 in females with Rett syndrome at the low dose and at the high dose and also announced written alignment with the FDA on the design of the pivotal study which will initiate in 3Q25, the analyst tells investors in a research note. Citizens views the data around the objectivity of the endpoint as a positive, along with the alignment with the FDA.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue